User Photo Cancer-News
Naveen Pemmaraju, MD @doctorpemm @MDAndersonNews #BPDCN #Cancer #Research Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, MD @doctorpemm @MDAndersonNews #BPDCN #Cancer #Research Blastic Plasmacytoid Dendritic Cell Neoplasm
Scott Howell, DO @Echosens #BreastCancer #NAFLD #NASH #Cancer #Research Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence
Scott Howell, DO @Echosens #BreastCancer #NAFLD #NASH #Cancer #Research Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence
Lee Zuckerman, MD @cityofhope #CTOS20 #cancer #research #MagneticGrowing Use of Magnetic Growing Intramedullary Nails with Intercalary Allograft Reconstruction after Tumor Resection
Lee Zuckerman, MD @cityofhope #CTOS20 #cancer #research #MagneticGrowing Use of Magnetic Growing Intramedullary Nails with Intercalary Allograft Reconstruction after Tumor Resection
Smith Giri, MD, MHS @smith__giri @UAB_ICOS @uabmedicine @UABNews #multiplemyeloma #cancer #research Evaluation of Daratumumab for the Treatment of Multiple Myeloma
Smith Giri, MD, MHS @smith__giri @UAB_ICOS @uabmedicine @UABNews #multiplemyeloma #cancer #research Evaluation of Daratumumab for the Treatment of Multiple Myeloma
Kirollos S. Hanna, PharmD @MHealthFairview @MayoMedEd @MayoClinic #MultipleMyeloma #cancer #research Emerging Therapies in Management of Multiple Myeloma and Best Practices
Kirollos S. Hanna, PharmD @MHealthFairview @MayoMedEd @MayoClinic #MultipleMyeloma #cancer #research Emerging Therapies in Management of Multiple Myeloma and Best Practices
Andrés Cervantes, MD @AndresC27622123 @Pivotal #gastrointestialcancer #cancer #research Phase IIa trial to examine Gastro-Intestinal cancer therapy
Andrés Cervantes, MD @AndresC27622123 @Pivotal #gastrointestialcancer #cancer #research Phase IIa trial to examine Gastro-Intestinal cancer therapy
User Photo Annual-Meeting
Barbara Burtness, MD @BarbaraBurtness @YaleCancer @FoxChaseCancer #ASCO20 #NANC #HNSCC Correlation of TMB with CDKN2A and TP53 mutation in HPV-negative HNSCC
Barbara Burtness, MD @BarbaraBurtness @YaleCancer @FoxChaseCancer #ASCO20 #NANC #HNSCC Correlation of TMB with CDKN2A and TP53 mutation in HPV-negative HNSCC
Andrzej Jakubowiak, MD, Ph.D. @UCCancerCenter #ASCO20 #multiplemyeloma Update of the phase 1/2 EVOLVE study
Andrzej Jakubowiak, MD, Ph.D. @UCCancerCenter #ASCO20 #multiplemyeloma Update of the phase 1/2 EVOLVE study
Paul G. Richardson, MD @DanaFarber #multiplemyeloma First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone
Paul G. Richardson, MD @DanaFarber #multiplemyeloma First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone
Eric Jonasch, MD @MDANdersonNews #ASCO20 #renalcellcarcinoma #vonhippellindau #VHL Phase II study of the oral HIF-2α inhibitor MK-6482
Eric Jonasch, MD @MDANdersonNews #ASCO20 #renalcellcarcinoma #vonhippellindau #VHL Phase II study of the oral HIF-2α inhibitor MK-6482
Robert Coleman, MD, FACOG, FACS @USOResearch #ASCO20 #SSC #PBC #ovariancancer A phase III randomized controlled trial of secondary surgical cytoreduction
Robert Coleman, MD, FACOG, FACS @USOResearch #ASCO20 #SSC #PBC #ovariancancer A phase III randomized controlled trial of secondary surgical cytoreduction
Erik A. Williams, MD @FoundationATCG #softtissuesarcoma CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1
Erik A. Williams, MD @FoundationATCG #softtissuesarcoma CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1
User Photo kidneycancer
Role of Radiation in Kidney Cancer
Role of Radiation in Kidney Cancer
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Modern Imaging Technology
Modern Imaging Technology
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
User Photo obr
Oral Therapies in the Treatment of Myeloid Malignancies @YaleCancer
Oral Therapies in the Treatment of Myeloid Malignancies @YaleCancer
RWE in Older Patients with Acute Myeloid Malignancies
RWE in Older Patients with Acute Myeloid Malignancies
Role of Venetoclax in Treatment of MDS @YaleCancer
Role of Venetoclax in Treatment of MDS @YaleCancer
PRIMO Study Investigating Duvelisib in PTCL
PRIMO Study Investigating Duvelisib in PTCL
Novel Approaches in Development for the Treatment of PTCL
Novel Approaches in Development for the Treatment of PTCL
Studies in PTCL
Studies in PTCL
User Photo VJHemOnc
Accelerating clinical trials in transplantation
Accelerating clinical trials in transplantation
Whole genome sequencing opens door for targeted Waldenström’s therapy
Whole genome sequencing opens door for targeted Waldenström’s therapy
Updated POLLUX results for early relapsed myeloma patients
Updated POLLUX results for early relapsed myeloma patients
Targeting BCMA with bispecific antibodies in R/R myeloma
Targeting BCMA with bispecific antibodies in R/R myeloma
Monoclonal antibodies: current and future potential
Monoclonal antibodies: current and future potential
Plasma cell leukemia and extramedullary disease in multiple myeloma
Plasma cell leukemia and extramedullary disease in multiple myeloma
User Photo ESMO
Sumanta Pal, M.D. @montypal @CityofHope #ESMO20 #kidneycancer #cancer #research #COSMIC-021 COSMIC-021, Cabozantinib in Combination with Atezolizumab
Sumanta Pal, M.D. @montypal @CityofHope #ESMO20 #kidneycancer #cancer #research #COSMIC-021 COSMIC-021, Cabozantinib in Combination with Atezolizumab
Professor Benjamin Besse @BenjaminBesseMD @GustaveRoussy @UnivParisSaclay #ESMO20 #NSCLC #Cancer #Research Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer
Professor Benjamin Besse @BenjaminBesseMD @GustaveRoussy @UnivParisSaclay #ESMO20 #NSCLC #Cancer #Research Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer
Klaus Hoeflich, Ph.D. @BlueprintMeds #lungcancer Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity
Klaus Hoeflich, Ph.D. @BlueprintMeds #lungcancer Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity
Prof. Byoung Chul Cho, MD, Ph.D. @yonsei_u #ESMO20 #nonsmallcelllungcancer Amivantamab, an EGFR-MET bispecific antibody, in combination with lazertinib in advanced EGFR NSCLC
Prof. Byoung Chul Cho, MD, Ph.D. @yonsei_u #ESMO20 #nonsmallcelllungcancer Amivantamab, an EGFR-MET bispecific antibody, in combination with lazertinib in advanced EGFR NSCLC
Petros Grivas, MD, Ph.D. @PGrivasMDPhD, @fredhutch #ESMO20 #bladdercancer Avelumab 1L + BSC vs BSC alone for advanced urothelial carcinoma
Petros Grivas, MD, Ph.D. @PGrivasMDPhD, @fredhutch #ESMO20 #bladdercancer Avelumab 1L + BSC vs BSC alone for advanced urothelial carcinoma
Ramaprasad Srinivasan, M.D., Ph.D. @nciccr_uroonc @NCIResearchCtr @thenci #ESMO20 #HVL #vonhipple-lindau Phase II study of the oral HIF-2α inhibitor MK-6482 for VHL ccRCC: Update
Ramaprasad Srinivasan, M.D., Ph.D. @nciccr_uroonc @NCIResearchCtr @thenci #ESMO20 #HVL #vonhipple-lindau Phase II study of the oral HIF-2α inhibitor MK-6482 for VHL ccRCC: Update
User Photo HMP CME
COVID-19 & Hematologic Malignancies: Episode 7 - Infectious Disease Update
COVID-19 & Hematologic Malignancies: Episode 7 - Infectious Disease Update
COVID-19 & Hematologic Malignancies: Episode 6 - Myeloid Malignancies Update
COVID-19 & Hematologic Malignancies: Episode 6 - Myeloid Malignancies Update
COVID-19 & Hematologic Malignancies: Episode 5 - Patient Experience Update
COVID-19 & Hematologic Malignancies: Episode 5 - Patient Experience Update
COVID-19 & Hematologic Malignancies: Episode 4 - Effective Management & Patient Experience
COVID-19 & Hematologic Malignancies: Episode 4 - Effective Management & Patient Experience
COVID-19 & Hematologic Malignancies: Episode 3 - Myeloma Update
COVID-19 & Hematologic Malignancies: Episode 3 - Myeloma Update
COVID-19 & Hematologic Malignancies: Episode 2 - Lymphoma Update
COVID-19 & Hematologic Malignancies: Episode 2 - Lymphoma Update
User Photo AxoProtego
AxoProtego Therapeutics, LLC is committed to individuals worldwide who suffer from, or are at risk for peripheral neuropathy. There are many causes of peripheral neuropathy. Our initial focus is neuropathy caused by chemotherapy, also known as Chemotherapy-Induced Peripheral Neuropathy (CIPN). We are dedicated to the discovery, development and commercialization of novel small molecule therapies that protect the neurons from degenerating so that neuropathy never develops.
Allison Huegel COO of AxoProtego and Ahmet Hoke, MD, Ph.D. @HopkinsMedicine #chemotherapyinducedperipheralneuropathy #neuropathy Novel Investigational Agent for Chemotherapy-Induced Perip...
Allison Huegel COO of AxoProtego and Ahmet Hoke, MD, Ph.D. @HopkinsMedicine #chemotherapyinducedperipheralneuropathy #neuropathy Novel Investigational Agent for Chemotherapy-Induced Perip...
User Photo VJOncology
BOPA18__VJO_Rachel Elliott_01
BOPA18__VJO_Rachel Elliott_01
New models for patient care: advanced pharmacy practitioners
New models for patient care: advanced pharmacy practitioners
Patient symptom and experience trackers
Patient symptom and experience trackers
Update from the Scottish Cancer Medicines Outcome Programme
Update from the Scottish Cancer Medicines Outcome Programme
The switch to biosimilar rituximab at UCH: 12 months on
The switch to biosimilar rituximab at UCH: 12 months on
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
User Photo cancergrace
The Global Resource for Advancing Cancer Education (GRACE) provides expert-mediated information on current and emerging cancer management options in order to empower patients, caregivers, and health professionals to become direct partners in cancer care.
Lung Cancer Video Library 2020 - PATEL Emerging Molecular Targets in NSCLC  EGFR Exon 20
Lung Cancer Video Library 2020 - PATEL Emerging Molecular Targets in NSCLC EGFR Exon 20
Lung Cancer Video Library 2020 - PATEL Emerging Molecular Targets in NSCLC  KRAS
Lung Cancer Video Library 2020 - PATEL Emerging Molecular Targets in NSCLC KRAS
Lung Cancer Video Library 2020 - BAUML - Emerging Molecular Targets in NSCLC  MET
Lung Cancer Video Library 2020 - BAUML - Emerging Molecular Targets in NSCLC MET
Lung Cancer Video Library 2020 - BAUML - Emerging Molecular Targets in NSCLC,  RET Fusions
Lung Cancer Video Library 2020 - BAUML - Emerging Molecular Targets in NSCLC, RET Fusions
Lung Cancer Video Library 2020 - LEVY -  Immunotherapy in Patients with Driver Mutations
Lung Cancer Video Library 2020 - LEVY - Immunotherapy in Patients with Driver Mutations
Lung Cancer Video Library 2020 - LEVY -  Immunotherapy in Patients with Driver Mutations
Lung Cancer Video Library 2020 - LEVY - Immunotherapy in Patients with Driver Mutations